noom glp-1 review Retention, Renewal, Results: Noom's GLP‑1 Companion Closing the GLP-1 Care Gap
Description
GLP-1 medications prescribing trends from 20182024 reveal shifts in semaglutide and tirzepatide use for type 2 diabetes and obesity.
Following the predefined inclusion and exclusion criteria, 36 studies were included in this systematic review and underwent qualitative analysis
Satiety regulation (reduces appetite, aiding in weight loss)
Find out how now.
Easy once-a-day use
